Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …

Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …

Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …

Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …

A randomised controlled trial 1 found no significant benefit of lopinavir–ritonavir over
placebo in patients with severe corona virus disease 2019 (COVID-19). Even though …

Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …

Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …

As the coronavirus disease 2019 (COVID-19) spreads, efforts are being made to reduce
transmission via standard public health interventions based on isolation of cases and tracing …

Objective To emulate a randomized target trial to estimate the association between the
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …

Background No therapeutics have yet been proven effective for the treatment of severe
illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open …